175 related articles for article (PubMed ID: 38384968)
1. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.
Sun J; Tian T; Wang N; Jing X; Qiu L; Cui H; Liu Z; Liu J; Yan L; Li D
Front Endocrinol (Lausanne); 2024; 15():1338420. PubMed ID: 38384968
[TBL] [Abstract][Full Text] [Related]
2. Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients.
Xie GS; Li G; Li Y; Pu JX; Huang YH; Li JH; Yin HM
Chin Med J (Engl); 2019 Nov; 132(22):2684-2689. PubMed ID: 31725446
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic effectiveness of serum sialic acid predicts both qualitative and quantitative prostate cancer in patients with prostate-specific antigen between 4 and 20 ng/mL.
Sun J; Yan L
Front Endocrinol (Lausanne); 2023; 14():1188944. PubMed ID: 37645415
[TBL] [Abstract][Full Text] [Related]
4. Elevated Serum Sialic Acid Levels Predict Prostate Cancer As Well As Bone Metastases.
Zhang C; Yan L; Song H; Ma Z; Chen D; Yang F; Fang L; Li Z; Li K; Li D; Yu N; Liu H; Xu Z
J Cancer; 2019; 10(2):449-457. PubMed ID: 30719139
[No Abstract] [Full Text] [Related]
5. Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma.
Chen Y; Lin Y; Nie P; Jiang W; Liu Y; Yuan R; Li M; Zhao S; Lin H; Li P; Zhang J; Hu Z; Xu J; Zhu X
Med Sci Monit; 2017 Apr; 23():1768-1774. PubMed ID: 28400549
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients.
Peng C; Juan C; Mao W; Jinghe Y; Renli T
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3832-3839. PubMed ID: 35731052
[TBL] [Abstract][Full Text] [Related]
8. The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer.
Yu Z; Yuan M; Chen G
Eur J Med Res; 2023 Dec; 28(1):587. PubMed ID: 38093347
[TBL] [Abstract][Full Text] [Related]
9. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
10. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
11. A novel prognostic model for Japanese patients with newly diagnosed bone-metastatic hormone-naïve prostate cancer.
Miyoshi Y; Yasui M; Yoneyama S; Kawahara T; Nakagami Y; Ohno Y; Iizuka J; Tanabe K; Hashimoto Y; Tsumura H; Tabata KI; Iwamura M; Yano A; Kawakami S; Uemura H
BJUI Compass; 2021 Mar; 2(2):105-114. PubMed ID: 35474890
[TBL] [Abstract][Full Text] [Related]
12. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Lorente JA; Valenzuela H; Morote J; Gelabert A
Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
15. Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.
Zhang JY; Ge P; Zhang PY; Zhao M; Ren L
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115239
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Factors Influencing Bone Metastasis in Prostate Cancer and Diagnostic Value of Serum PSA, CysC and D-D.
Liu X; Zhao C; Lin J; Liu B
Arch Esp Urol; 2024 Jan; 77(1):72-78. PubMed ID: 38374016
[TBL] [Abstract][Full Text] [Related]
17. [Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
Cheng Y; Luo LP; Hu S; Li LN; Wu C; Wu B; Wang DW
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):876-881. PubMed ID: 33113631
[No Abstract] [Full Text] [Related]
18. Should bone scan be performed in Chinese prostate cancer patients at the time of diagnosis?
Wang Y; Guo J; Xu L; Zhao N; Xu Z; Wang H; Zhu Y; Jiang S; Yang N; Yang Y; Wang G
Urol Int; 2013; 91(2):160-4. PubMed ID: 23548369
[TBL] [Abstract][Full Text] [Related]
19. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
Wolff JM; Bares R; Jung PK; Buell U; Jakse G
Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
